|
JP2011518555A
(ja)
|
2008-04-14 |
2011-06-30 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
標的組込みのための線形ドナーコンストラクト
|
|
AU2009283194B2
(en)
|
2008-08-22 |
2014-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
LT2975051T
(lt)
|
2009-06-26 |
2021-07-12 |
Regeneron Pharmaceuticals, Inc. |
Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
|
|
JP2013518602A
(ja)
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
LT3401400T
(lt)
|
2012-05-25 |
2019-06-10 |
The Regents Of The University Of California |
Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
|
|
PL4397760T3
(pl)
|
2012-10-23 |
2026-03-30 |
Toolgen Incorporated |
Kompozycja do rozszczepiania docelowego dna zawierająca prowadzące rna specyficzne dla docelowego dna i kwas nukleinowy kodujący białko cas lub białko cas oraz jej zastosowanie
|
|
EP3135765A1
(en)
|
2012-12-06 |
2017-03-01 |
Sigma-Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
SG10201912991WA
(en)
|
2012-12-17 |
2020-03-30 |
Harvard College |
Rna-guided human genome engineering
|
|
JP2016507244A
(ja)
|
2013-02-27 |
2016-03-10 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） |
Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
|
|
US10378027B2
(en)
|
2013-03-15 |
2019-08-13 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
AU2015218576B2
(en)
|
2014-02-24 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
EP3674408A1
(en)
|
2014-06-16 |
2020-07-01 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas
|
|
US20150376587A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
EP3237624B1
(en)
|
2014-12-23 |
2020-01-29 |
Syngenta Participations AG |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
JP6851319B2
(ja)
*
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2017004279A2
(en)
|
2015-06-29 |
2017-01-05 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
SI3436077T1
(sl)
|
2016-03-30 |
2025-07-31 |
Intellia Therapeutics, Inc. |
Formulacije lipidnih nanodelcev za komponente crispr/cas
|
|
MY206324A
(en)
|
2016-12-08 |
2024-12-10 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
EP3687581A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
FI3688162T3
(fi)
|
2017-09-29 |
2024-05-15 |
Intellia Therapeutics Inc |
Formulaatioita
|
|
EP3759226A4
(en)
*
|
2018-03-02 |
2022-06-15 |
Generation Bio Co. |
IDENTIFICATION AND CHARACTERIZATION OF GENOMIC SAFE HARBOR (GSH) IN HUMAN AND MURINE GENOMES AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT IDENTIFIED GSH LOCI
|
|
WO2020069296A1
(en)
|
2018-09-28 |
2020-04-02 |
Intellia Therapeutics, Inc. |
Compositions and methods for lactate dehydrogenase (ldha) gene editing
|
|
BR112021007301A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
composições e métodos para expressar fator ix
|
|
EP3867376A1
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
SG11202103733SA
(en)
|
2018-10-18 |
2021-05-28 |
Intellia Therapeutics Inc |
Compositions and methods for transgene expression from an albumin locus
|
|
AU2020348776A1
(en)
*
|
2019-09-17 |
2022-05-05 |
Memorial Sloan-Kettering Cancer Center |
Genomic safe harbors for transgene integration
|
|
WO2021055592A1
(en)
*
|
2019-09-17 |
2021-03-25 |
Memorial Sloan-Kettering Cancer Center |
Methods for identifying genomic safe harbors
|